Owen A O’Connor, MD, PhD from the Columbia University Medical Center Center for Lymphoid Malignancies, New York, NY, presents the results of the first multicenter, randomized Phase III study (NCT01482962) in patients with relapsed/refractory (R/R) peripheral T-cell lymphoma (PTCL), which evaluated alisertib vs the investigator’s choice (pralatrexate, romidepsin or gemcitabine). Alisertib is a selective inhibitor of Aurora A kinase but it was not found to be superior to the comparator arm in terms of progression-free survival (PFS). He explains some of the key findings and also talks about data from another study showing a synergy between alisertib and romidepsin.
The results were presented at the American Society of Hematology (ASH) 2015 Annual Meeting in Orlando, FL.